WHO ICTRP trial
Effect of Lipid lowering Drug vAtorvastatin in Steroid resistance Nephrotic…
CTRI/2012/07/002761 · Clinical Trials Registry India (CTRI) · Recruiting
Key facts
| Trial ID | CTRI/2012/07/002761 |
|---|---|
| Public title | Effect of Lipid lowering Drug vAtorvastatin in Steroid resistance Nephrotic syndrome |
| Scientific title | Effect of atorvastatin on hyperlipidemia and progression of carotid intima media thickness in steroid resistance nephrotic syndrome: A randomized controlled trial |
| Primary sponsor | ICMR |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Countries | India |
| Conditions | Health Condition 1: null- Steroid Resistant Nephrotic Syndrome with hyperlipidemia |
| Interventions | Intervention1: Atorvastatin: Atorvastain 10mg per day for one year per oral Control Intervention1: Placebo: Placebo in same dose Per oral |
| Registration date | Apr 7, 2012 |
| Target size | 50 |
| Secondary IDs | CT-Drugs/68/2010 |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: